Whole proteome time course experiment in SJSA-1 cells
Ontology highlight
ABSTRACT: Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we test the effect of Navtemadlin treatment on protein expression in SJSA-1 cells over the course of 24 h.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
SUBMITTER:
Amrita Date
LAB HEAD: Anna Barnard
PROVIDER: PXD058053 | Pride | 2025-04-28
REPOSITORIES: Pride
ACCESS DATA